Intranasal erythropoietin therapy in nervous system disorders

Genç, Şermin; Zadeoğluları, Zeynep; Öner, Meryem Gülfem; Genç, Kürşad; Digicaylioglu, Murat

doi:10.1517/17425247.2011.540236

Cited by 19 publications

(15 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another clinical disadvantage is the necessity to administer EPO intravenously or subcutaneously, which is unpleasant and expensive. Evidence of neuroprotective effects of intranasal delivery of EPO in rats (Garcia-Rodriguez and Sosa-Teste 2009; Genc et al 2011;Yu et al 2005) therefore deserves to be followed up by investigation of the neurocognitive effects in humans. Intranasal application necessitates significantly smaller doses of EPO for neuroprotection, which would help overcome the problems associated with hematopoietic effects of larger doses.…”

Section: Discussionmentioning

confidence: 99%

Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

et al. 2011

View full text Add to dashboard Cite

The reviewed studies demonstrate beneficial effects of EPO on hippocampus-dependent memory function and on depression-relevant behavior, thus highlighting EPO as a candidate agent for future management of cognitive dysfunction and mood symptoms in depression. Larger-scale clinical trials of EPO as a treatment for mood and neurocognitive symptoms in patients with mood disorder are therefore warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However studies conducted on the passage of molecules by the intranasal route in species such as nonhuman primate Macaca fascicularis species are recommended for pharmacokinetic studies of the nasal [45,60]. The transit of Neuro-EPO to the CNS after intranasal administration and its effect were reported by us [41]. The detection of the molecule either in the olfactory bulbs or in the cerebellum suggested its contact with the CSF.…”

Section: Security and Efficacy Of The Nasal Neuro-epo Intra Nasally Pmentioning

confidence: 98%

“…EPO has been used in millions of peoples for over 20 years with very few adverse effects reported. The application of EPO and its non-erythropoetic variants like Neuro-EPO through nasal delivery to the central nervous system target an area of great interest right now [39][40][41]. In cynomolgus monkeys, intra nasal route is relatively well known anatomically, physiologically as well as the transport mechanism of low molecular weight molecules and proteins to the brain [42].…”

Section: Delivery Of Drugs To Cns and Bbbmentioning

confidence: 99%

“…Possible routes for the molecules of the nasal cavity to the brain may involve several mechanisms as bulk flow and diffusion within perineural channels, perivascular spaces, or lymphatic channels directly connected to brain tissue or CSF [40]. It is known that the trigeminal nerve innervates the nasal cavity and provides a direct connection to CNS, a description of these pathways and Genc (2011) in an excellent Expert Opinion [41] has recently reported processes.…”

Section: Delivery Of Drugs To Cns and Bbbmentioning

confidence: 99%

See 1 more Smart Citation

Neuro-EPO by Nasal Route as a Neuroprotective Therapy in Brain Ischemia

Bretón¹

2012

Acute Ischemic Stroke

View full text Add to dashboard Cite

“…EPO is an erythropoietic cytokine that possesses broad spectrum neuroprotective properties and is under investigation by the intranasal route for a number of CNS disorders 204 .…”

Section: Erythropoietinmentioning

confidence: 99%

intranasal GDNF gene therapy approach for treating Parkinson's disease

Aly¹

View full text Add to dashboard Cite

Abstract:Parkinson's disease (PD) is a progressive neurodegenerative disorder that results from the loss of the A9 nigrostriatal dopamine neurons. The current therapies available for treating PD provide symptomatic relief by replacing or mimicking dopamine in the brain, but do not actually prevent or reverse the loss of these dopaminergic neurons. Glial cell--line derived neurotrophic factor (GDNF) has disease--modifying potential in PD due to its ability to promote the survival of dopamine neurons both in vitro and in vivo. GDNF has been shown to be neuroprotective in several animal models of PD. However, its clinical potential has been limited thus far by its inability to cross the blood--brain barrier (BBB) and the need for invasive intracranial delivery. The main objective of this thesis was to develop an approach to non--invasively deliver a continuous source of GDNF to the brain at levels that are neuroprotective inParkinson's Disease, whilst minimizing systemic exposure. To do so, this project investigated the intranasal delivery of non--viral hGDNF expression plasmids (pGDNF_1b and pUGG) compacted into nanoparticles (NPs). Intranasal delivery allows large therapeutics to circumvent the BBB while avoiding peripheral exposure, while a gene therapy approach would provide a long--term renewable source of GDNF in the brain regions associated with PD. These NPs, developed by Copernicus Therapeutics, Inc., are composed of 10 kDa polyethylene glycol--substituted lysine 30--mers (CK30PEG10k) which unimolecularly compact the plasmid DNA into neutrally charged NPs.The first goal of this project was to determine if intranasal administration of pGDNF_1b DNA NPs produces a neuroprotective and neurotrophic effect on rat substantia nigra (SN)

show abstract

Intranasal erythropoietin therapy in nervous system disorders

Cited by 19 publications

References 83 publications

Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

Neuro-EPO by Nasal Route as a Neuroprotective Therapy in Brain Ischemia

intranasal GDNF gene therapy approach for treating Parkinson's disease

Contact Info

Product

Resources

About